Cargando…

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development

BACKGROUND: Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) monotherapy is recommended as initial treatment for Global Initiative for Chronic Obstructive Lung Disease (GOLD) groups B, C, and D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anzueto, Antonio, Miravitlles, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389564/ https://www.ncbi.nlm.nih.gov/pubmed/32727455 http://dx.doi.org/10.1186/s12931-020-01407-y

Ejemplares similares

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?
por: Miravitlles, Marc, et al.
Publicado: (2017)

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
por: Alvarado-Gonzalez, Alcibey, et al.
Publicado: (2015)

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
por: Rutten-van Mölken, Maureen P. M. H., et al.
Publicado: (2007)

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

The Combination of Tiotropium and Budesonide in the Treatment of Chronic Obstructive Pulmonary Disease
por: Um, Sang-Won, et al.
Publicado: (2007)

Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
por: Restrepo, Marcos I., et al.
Publicado: (2018)

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium
por: Beeh, Kai-Michael, et al.
Publicado: (2012)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

Optimizing management of chronic obstructive pulmonary disease in the upcoming decade
por: Russell, Richard, et al.
Publicado: (2011)

Chronic obstructive pulmonary disease
por: Decramer, Marc, et al.
Publicado: (2012)

Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease
por: Sethi, S., et al.
Publicado: (2015)

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat(®) fixed-dose combination for chronic obstructive pulmonary disease patients in Italy
por: Selya-Hammer, Carl, et al.
Publicado: (2016)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis
por: He, Jie, et al.
Publicado: (2020)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease
por: Naik, Shalini, et al.
Publicado: (2010)

Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease
por: Halpern, Rachel, et al.
Publicado: (2011)

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Yu, Suyun, et al.
Publicado: (2021)

A comparison of tiotropium/olodaterol vs tiotropium alone in terms of treatment effect for chronic obstructive pulmonary disease: A meta-analysis: Retraction
Publicado: (2020)

Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management
por: Singh, Dave, et al.
Publicado: (2016)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
por: Miravitlles, Marc, et al.
Publicado: (2017)

Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients
por: Yoshimura, Kenji, et al.
Publicado: (2012)

Efficacy of budesonide/formoterol and tiotropium combination for the treatment of Chinese patients with chronic obstructive pulmonary disease
por: Feng, Jun-fei, et al.
Publicado: (2018)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
por: Chatterjee, Arjun, et al.
Publicado: (2012)

A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
por: Miravitlles, Marc, et al.
Publicado: (2017)

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy
por: Carone, Mauro, et al.
Publicado: (2020)

Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden
por: Eklund, Oskar, et al.
Publicado: (2015)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
por: Jayanthi, Nalini, et al.
Publicado: (2022)

The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease
por: Gong, Yinhua, et al.
Publicado: (2022)

Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review
por: dos Santos, Natasha Cordeiro, et al.
Publicado: (2022)

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials
por: Cooper, Christopher B, et al.
Publicado: (2011)

Tiotropium safety in ‘real‐world’ populations: Response to Schmiedl, et al. in the British Journal of Clinical Pharmacology
por: Wise, Robert, et al.
Publicado: (2016)

Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting
por: Gauhar, Umair, et al.
Publicado: (2009)

Bronchodilator Effect of Tiotropium via Respimat(Ⓡ) Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Ogasawara, Takashi, et al.
Publicado: (2017)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
por: Shah, Dhvani, et al.
Publicado: (2018)

Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease
por: Lopez-Campos, José Luis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_igid4hnn3lmo73au7qd8elh3dc